ASCO 2023: INDIGO Trial of Vorasidenib for Select Patients With Brain Tumors
Posted: 06/05/2023 | By: Chase Doyle

In the INDIGO trial, presented by Mellinghoff et al at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers tested the efficacy of vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, in patients with brain tumors (Abstract LBA1).

Question 1 of 5

What type of brain tumor did vorasidenib target in this study?

Choose 1